The effects of docosahexaenoic acid supplementation on cognition and well-being in mild cognitive impairment: A 12-month randomised controlled trial.

Int J Geriatr Psychiatry · 2022 · PMC9321856 · PMID 35373862

Europe PMC DOI

hedged sentence

0.0900

closest p · 1.8× alpha

0.0900

boldest claim

The sentences

showed a trendp = 0.09so close (0.05 < p ≤ 0.1)

The only treatment effect detected in the current trial was in systolic blood pressure, although the results showed a trend towards an improvement in SF‐36 bodily pain scores ( p = 0.09, ƞ 2 = 0.05) in the DHA group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.